Related references
Note: Only part of the references are listed.
Letter
Hematology
Margherita Rosati et al.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Infectious Diseases
Wan Ni Chia et al.
Summary: The study investigated the dynamics of neutralising antibody response in patients who have recovered from COVID-19, finding great variations and suggesting that predicting immune longevity can only be accurately determined at the individual level. The findings emphasize the importance of public health and social measures in the ongoing pandemic outbreak response, and may have implications for the longevity of immunity after vaccination.
Article
Medicine, General & Internal
Timothy Farinholt et al.
Summary: This study identified a cluster of 6 vaccinated patients infected with the delta variant, suggesting immune evasion in patients who received the Pfizer BNT162b2, Moderna mRNA-1273, and Covaxin BBV152 vaccines. The delta variant may pose the highest risk among currently circulating SARS-CoV-2 variants, with increased transmissibility over the alpha variant and potential vaccine breakthrough.
Article
Multidisciplinary Sciences
Christian Gaebler et al.
Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.
Article
Multidisciplinary Sciences
Jennifer M. Dan et al.
Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Multidisciplinary Sciences
Yannic C. Bartsch et al.
Summary: The study reveals significant heterogeneity in antibody responses following SARS-CoV-2 infection, with limited decay of antibody titers over time. Observing neutralization, Fc-function, and SARS-CoV-2 specific T cell responses requires reaching a certain threshold of receptor-binding domain (RBD)-specific antibody titers, indicating a switch-like relationship between antibody titer and function.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Maureen Betton et al.
Summary: After COVID-19 infection, levels of IgG antibodies and neutralization activity against SARS-CoV-2 decrease over time, but do not imply loss of neutralizing capacity; A few patients showed negative serological status 6 months post-infection; IgG levels correlate with neutralization and show a stronger correlation for anti-S antibodies.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Evangelos Terpos et al.
Summary: The study found that antibody responses against SARS-CoV-2 decreased over time, with Spike antibodies showing longer persistence. The antibody decay followed a biphasic trend, with more pronounced decrease in the first 6 months. The longevity and neutralizing ability of antibodies against Spike and Spike-RBD should be considered in future vaccination strategies.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Microbiology
Vasiliki Pappa et al.
Summary: A multicenter phase II study evaluated the efficacy and safety of convalescent plasma (CP) in severe COVID-19 patients, finding that CP recipients had significantly reduced risk of death, improved overall survival, and higher chances of extubation. Higher levels of antibodies in the CP were associated with reduced risk of death, and CP infusion was safe with minimal adverse events. Early use of CP may be a safe and effective treatment for severe COVID-19 patients.
Article
Urology & Nephrology
Gaetano Alfano et al.
Summary: Recent studies have shown that dialysis patients who recovered from severe COVID-19 were able to produce a durable anti-spike protein seroconversion, with an average antibody titer of 212.6 +/- 174.9 UA/ml after one year from diagnosis. The long-term protective capacity of this immune response remains to be determined.
HEMODIALYSIS INTERNATIONAL
(2021)
Article
Immunology
Mar Masia et al.
Summary: The durability of anti-spike IgG antibodies remains detectable one year after hospitalization for COVID-19. Higher peak antibody titres and disease severity were associated with increased durability of detectable antibodies.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Immunology
Stephane Pelleau et al.
Summary: A multiplex serological test was developed to diagnose and estimate the time since SARS-CoV-2 infection, aiding in reconstructing past epidemics.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Amarendra Pegu et al.
Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.
Article
Virology
Thomas P. Thomopoulos et al.
Summary: A study followed 31 Convalescent Plasma (CP) recipients longitudinally, showing that patients with low immune responses had significant increases in antibodies to all SARS-CoV-2 proteins and neutralizing antibodies within 2 weeks, while those with high immune responses demonstrated similar virus clearance trends as the former.
Article
Cell Biology
Cristina Bergamaschi et al.
Summary: Early responses to vaccination play a crucial role in shaping both humoral and cellular protective immunity. This study characterizes cytokine and chemokine responses after the first and second dose of the BNT162b2 mRNA vaccine, highlighting the potential for biomarkers like IL-15 and IFN-gamma in predicting humoral immunity development. In previously COVID-19-infected individuals, a single vaccination can trigger strong cytokine induction and antibody responses similar to those seen in naive individuals upon booster vaccination, with implications for future public health recommendations.
Article
Medicine, General & Internal
Fiona Tea et al.
Summary: The study found that a broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 was associated with high viral neutralization, which was related to COVID-19 severity. Some high responders maintained high neutralizing responses over time, making them ideal convalescent plasma donors. Antibodies generated during the first wave of COVID-19 had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC.
Article
Microbiology
Margherita Rosati et al.
Summary: Both DNA and mRNA vaccines have shown promise in animal models, with DNA vaccines demonstrating protective efficacy and immunogenicity against SARS-CoV-2 in rhesus macaques. DNA vaccine regimens can induce potent antibody and T cell responses, with the co-immunization of protein showing superior effectiveness.
Article
Public, Environmental & Occupational Health
Catherine M. Brown et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Microbiology
Alena J. Markmann et al.
Summary: In this study, it was found that neutralizing antibody responses in COVID-19 convalescent individuals vary in magnitude but are durable. Higher neutralizing antibody titers are independently and significantly associated with male sex, as well as with increased age and symptom grade in male donors. Cardiometabolic comorbidities are also associated with higher antibody titers independently of sex.
Article
Medicine, General & Internal
Floriane Gallais et al.
Summary: The study revealed a triphasic kinetic model of SARS-CoV-2 antibodies in convalescent individuals, showing long-term persistence and reduced risk of reinfection. Vaccination significantly increased antibody titers, enhancing protection against variants.
Article
Cell Biology
Sai Priya Anand et al.
Summary: Recent research on convalescent individuals of COVID-19 has shown a decline in antibody levels in plasma, while specific memory B cells remain present. IgM antibodies against Spike and RBD decay rapidly, whereas IgG decline is less significant. Understanding these immune memory responses is crucial for secondary infection prevention and vaccine efficacy.
CELL REPORTS MEDICINE
(2021)
Article
Medicine, Research & Experimental
Natalia Sherina et al.
Summary: The study shows that 85% of samples from COVID-19 patients had anti-SARS-CoV-2 antibodies within 4 weeks of symptom onset, while specific IgG antibodies and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. 80% of samples collected at 6-8 months after symptom onset still had anti-SARS-CoV-2 IgG antibodies, and specific memory B and T cell responses continued to develop and persist.
Article
Immunology
Katharine H. D. Crawford et al.
Summary: Antibody levels, including neutralizing antibodies, decline after SARS-CoV-2 infection, with a 4-fold average decrease in titers from 1 to 4 months after symptom onset. This decline is accompanied by a decrease in total antibodies capable of binding the viral spike protein. Further studies are needed to determine the long-term durability of immunity to SARS-CoV-2, including examination of long-lived B cells and antibody titers over extended periods.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Frauke Muecksch et al.
Summary: Understanding the longitudinal trajectory of SARS-CoV-2 antibodies is crucial for diagnosis and immunity prediction. Different serological assays have varying suitability for surveillance and prediction of neutralization potency, with S-based assays better predicting neutralization levels over time.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Virology
Chuanmiao Liu et al.
Summary: The study revealed that IgG antibody levels remained stable in convalescent patients while IgM antibody levels decreased in early convalescence and were only detected in a few patients after six months, with higher IgG levels observed in severe and critical groups compared to moderate cases. Further investigation is needed to determine if these specific antibodies provide long-term protection in recovered COVID-19 patients.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Immunology
Alexandra Rockstroh et al.
Summary: Studying the humoral protective immune response post SARS-CoV-2 infections is crucial for assessing reinfection risk, improving diagnostic methods, and evaluating vaccine trials. This research analyzed the dynamics of neutralizing antibodies and IgG responses in COVID-19 patients, identifying potential diagnostic markers for estimating neutralizing protection.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Immunology
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Article
Multidisciplinary Sciences
Davide F. Robbiani et al.
Letter
Medicine, General & Internal
F. Javier Ibarrondo et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Immunology
Patricia Figueiredo-Campos et al.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2020)
Article
Oncology
Yun Tan et al.
FRONTIERS OF MEDICINE
(2020)
Article
Microbiology
Jeffrey Seow et al.
NATURE MICROBIOLOGY
(2020)
Article
Microbiology
Evangelos Terpos et al.
Letter
Medicine, General & Internal
Edwin Boelke et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
